Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 17;14:252. doi: 10.1038/s41467-023-35880-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Dose-response curves after treatment with olaparib for MMS22L- or TONSL-KO cells versus corresponding AAVS1 control cells of C4-2B, LNCaP, MDAPCa2b, 22Rv1, DU145 and PC-3. Upper right panels are immunoblot analysis of MMS22L or TONSL KO efficiency. ACTB (β-actin) is a loading control. The olaparib response of MMS22L-KO C4-2B cells is presented in (2b). b Flow cytometry analysis of GFP and RFP positive cells. MMS22L-KO LNCaP or C4-2B cells (with GFP) were co-cultured with corresponding AAVS1 control cells (with RFP) in a 1:1 ratio in the presence of DMSO or olaparib. Two MMS22L-KO cell lines (sg1 and sg2) and one control cell line (sg1) were used. Cells were collected and analyzed using flow cytometry 7 days after the treatment. The percentage of each cell population is presented in each panel. The experiment was repeated independently twice with similar results. c Dose-response curves after treatment with rucaparib, talazoparib, veliparib, and carboplatin for two MMS22L-KO C4-2B cell lines (sg1 and sg2) versus two AAVS1 control cell lines (sg1 and sg2). d Dose-response curves (upper panel) after treatment with olaparib for AAVS1 control and MMS22L-KO C4-2B cell clones. Immunoblot analysis (lower panel) showing the MMS22L protein level in AAVS1 control and MMS22L-KO cell clones. e Immunoblot analysis (left panel) showing the MMS22L protein level in C4-2B AAVS1 control sg1 clone 1 (cl1) and MMS22L-KO sg1 clone 1 (cl1), stably infected with TET-inducible sgRNA-resistant MMS22L gene, after treatment with or without doxycycline (0.15 μg/ml) for 3 days. Dose-response curves (right panel) after olaparib treatment with or without doxycycline (0.15 μg/ml) treatment for the same C4-2B cell clones. In a and c–e data are presented as mean ± SD (n = 3 biologically independent experiments). The immunoblot analyses were repeated independently twice with similar results. The p-values were determined by two-way ANOVA. Source data are provided as a Source Data file.